Business Context and Reporting Period
Company: OraSure Technologies, Inc. (OSUR)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: OraSure develops, manufactures, and markets diagnostic products (HIV, HCV, Syphilis, Sickle Cell, Ebola) and sample management solutions. The company operates as a single reportable segment.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended June 30, 2026 |
6 Months Ended June 30, 2026 |
6 Months Ended June 30, 2025 |
|---|---|---|---|
| Net Revenues | $30,639 | $58,564 | $61,173 |
| Gross Profit | $13,317 | $25,121 | $25,458 |
| Gross Margin | 43.5% | 42.9% | 41.6% |
| Operating Income (Loss) | $5,440 | $(17,829) | $(35,776) |
| Net Income (Loss) | $6,249 | $(16,128) | $(35,733) |
| Diluted EPS | $0.09 | $(0.23) | $(0.48) |
| Cash and Equivalents | $160,582 | $160,582 | $234,578 |
| Working Capital | $197,818 | $197,818 | N/A |
Liquidity: Cash decreased by $38.7 million during the six months ended June 30, 2026, primarily due to operating cash outflows and stock repurchases. The company holds $160.6 million in cash, with 53% held by its Canadian subsidiary.
Material Changes vs. Prior Period
- Revenue Decline: Six-month net revenues decreased 4% to $58.6 million. This was driven by a 2% drop in Diagnostics revenue (lower HCV and HIV sales) and the discontinuation of the Risk Assessment Testing line. Sample Management Solutions revenue remained flat.
- Profitability Improvement: The company reported a net income of $6.2 million for the quarter, compared to a net loss of $19.7 million in the prior year quarter. The six-month operating loss narrowed significantly from $35.8 million to $17.8 million.
- Contingent Consideration Gain: A non-cash gain of $22.6 million (quarter) and $22.5 million (six months) was recorded due to a reduction in the fair value of acquisition-related contingent consideration. This resulted from the withdrawal of a CT/NG FDA submission, eliminating milestone payment obligations and reducing royalty liabilities.
- Expense Trends: R&D expenses decreased 17% in the quarter but increased 10% for the six months due to clinical trial costs. G&A expenses increased 14% in the quarter and 8% for the six months, largely due to legal fees and stockholder activism costs.
Guidance, Outlook, and Risks
- Regulatory Developments:
- Colli-Pee: Received FDA clearance in June 2026 for use with Roche's CT/NG/TV/MG tests.
- Ebola: Received Emergency Use Authorization (EUA) in July 2026 for the second-generation OraQuick Ebola Rapid Antigen Test.
- CT/NG Self-Test: Withdrew its 510(k) submission in July 2026 to pursue a new clinical trial, delaying expected FDA clearance and commercialization.
- Capital Allocation: The company repurchased $7.0 million of common stock during the six months ended June 30, 2026, under a $40.0 million program authorized in March 2025. Approximately $18.0 million remains available for repurchase.
- Litigation: Ongoing trade secrets litigation against NowDiagnostics, Inc. and former employees. Trial is scheduled for January 17, 2027. Management does not expect a material adverse effect.
- Risks: Key risks include reliance on sole-supply vendors, regulatory approval delays, foreign currency fluctuations, and the ability to fund R&D and operations without additional financing.
Investor Verification Checklist
- Non-Cash Income Impact: Verify the sustainability of profitability without the $22.5 million non-cash gain from contingent consideration adjustments.
- CT/NG Timeline: Monitor the timeline for the new clinical trial and subsequent FDA submission for the CT/NG self-test, as this impacts future royalty revenue and contingent liabilities.
- Cash Burn Rate: Assess the $23.8 million cash used in operating activities over six months against the $160.6 million cash balance to determine runway.
- Revenue Mix: Confirm the trajectory of HCV and HIV revenues, which declined due to program expirations and funding reductions.
- Legal Exposure: Track the status of the NowDiagnostics litigation and potential costs associated with the trial scheduled for early 2027.